Cassava Sciences Inc (SAVA)
2.89
+0.14
(+5.09%)
USD |
NASDAQ |
Jan 03, 16:00
2.88
-0.01
(-0.35%)
After-Hours: 20:00
Cassava Sciences SG&A Expense (Quarterly): 12.95M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| BridgeBio Pharma Inc | 68.82M |
| Alnylam Pharmaceuticals Inc | 220.99M |
| Altimmune Inc | 4.969M |
| PTC Therapeutics Inc | 73.46M |
| Scholar Rock Holding Corp | 16.06M |